These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 8670252)
21. Capillary liquid chromatography-tandem mass spectrometry of tetrahydroisoquinoline derived neurotoxins: a study on the blood-brain barrier of rat brain. Song Y; Xu J; Hamme A; Liu YM J Chromatogr A; 2006 Jan; 1103(2):229-34. PubMed ID: 16310796 [TBL] [Abstract][Full Text] [Related]
22. Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Yamakawa T; Kotake Y; Fujitani M; Shintani H; Makino Y; Ohta S Neurosci Lett; 1999 Nov; 276(1):68-70. PubMed ID: 10586977 [TBL] [Abstract][Full Text] [Related]
23. Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines. Antkiewicz-Michaluk L Pol J Pharmacol; 2002; 54(6):567-72. PubMed ID: 12866710 [TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468 [TBL] [Abstract][Full Text] [Related]
25. Detection of 1-phenyl-N-methyl-1,2,3,4-tetrahydroisoquinoline and 1-phenyl-1,2,3,4-tetrahydroisoquinoline in human brain by gas chromatography-tandem mass spectrometry. Kajita M; Niwa T; Fujisaki M; Ueki M; Niimura K; Sato M; Egami K; Naoi M; Yoshida M; Nagatsu T J Chromatogr B Biomed Appl; 1995 Jul; 669(2):345-51. PubMed ID: 7581910 [TBL] [Abstract][Full Text] [Related]
26. Effect of tetrahydroisoquinoline (TIQ), one of endogenous substances inducing parkinsonism, on isolated rat vas deferens. Koike K; Takayanagi I; Wani S; Yanagita T; Ohta S; Hirobe M Gen Pharmacol; 1989; 20(2):259-60. PubMed ID: 2714622 [TBL] [Abstract][Full Text] [Related]
27. Neurotoxins: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1,2,3,4-tetrahydroisoquinoline and 1-methyl-6,7-dihydroxy-tetrahydroisoquinoline as substrates for FAD-containing monooxygenase of porcine liver microsomes. Wu RF; Miura S; Ichikawa Y Biochem Pharmacol; 1992 Nov; 44(10):2079-81. PubMed ID: 1449525 [TBL] [Abstract][Full Text] [Related]
28. Sulphation of the heterocyclic amine 1,2,3,4-tetrahydroisoquinoline in the human liver and intestinal mucosa: interindividual variability. Pacifici GM; D'alessandro C; Gucci A; Giuliani L Arch Toxicol; 1997; 71(8):477-81. PubMed ID: 9248624 [TBL] [Abstract][Full Text] [Related]
29. Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. DeCuypere M; Lu Y; Miller DD; LeDoux MS J Neurochem; 2008 Dec; 107(5):1398-413. PubMed ID: 19013830 [TBL] [Abstract][Full Text] [Related]
30. Endogenous synthesis of N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of N-methylisoquinolinium ion, in the brains of primates with parkinsonism after systemic administration of 1,2,3,4-tetrahydroisoquinoline. Niwa T; Yoshizumi H; Tatematsu A; Matsuura S; Yoshida M; Kawachi M; Naoi M; Nagatsu T J Chromatogr; 1990 Nov; 533():145-51. PubMed ID: 2127934 [No Abstract] [Full Text] [Related]
31. Tetrahydroisoquinoline derivatives of enkephalins: synthesis and properties. Foppoli C; Coccia R; Blarzino C; Cini C; Rosei MA Biochem Pharmacol; 2002 May; 63(10):1885-92. PubMed ID: 12034373 [TBL] [Abstract][Full Text] [Related]
32. A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease. Xie B; Lin F; Ullah K; Peng L; Ding W; Dai R; Qing H; Deng Y Biochem Biophys Res Commun; 2015 Apr; 459(3):361-6. PubMed ID: 25744031 [TBL] [Abstract][Full Text] [Related]
33. [The search for endogenous or exogenous MPTP-like substances]. Nagatsu T Rinsho Shinkeigaku; 1989 Dec; 29(12):1497-500. PubMed ID: 2517047 [TBL] [Abstract][Full Text] [Related]
34. Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system. Lorenc-Koci E; Antkiewicz-Michaluk L; Wardas J; Zapała M; Wierońska J Brain Res; 2004 May; 1009(1-2):67-81. PubMed ID: 15120584 [TBL] [Abstract][Full Text] [Related]
35. Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum. Wąsik A; Romańska I; Antkiewicz-Michaluk L Neurotox Res; 2016 Nov; 30(4):648-657. PubMed ID: 27568335 [TBL] [Abstract][Full Text] [Related]
36. Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. Naoi M; Maruyama W; Niwa T; Nagatsu T J Neural Transm Suppl; 1994; 41():197-205. PubMed ID: 7931227 [TBL] [Abstract][Full Text] [Related]
37. A chiral synthesis of four stereoisomers of 1,3-dimethyl-1,2,3,4-tetrahydroisoquinoline, an inducer of Parkinson-like syndrome. Toda J; Matsumoto S; Saitoh T; Sano T Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):91-8. PubMed ID: 10705483 [TBL] [Abstract][Full Text] [Related]
38. Opposite effect of simple tetrahydroisoquinolines on amphetamine- and morphine-stimulated locomotor activity in mice. Vetulani J; Nalepa I; Antkiewicz-Michaluk L; Sansone M J Neural Transm (Vienna); 2001; 108(5):513-26. PubMed ID: 11459073 [TBL] [Abstract][Full Text] [Related]
39. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. Yoshida M; Ogawa M; Suzuki K; Nagatsu T Adv Neurol; 1993; 60():207-11. PubMed ID: 8093578 [TBL] [Abstract][Full Text] [Related]
40. Presence of tetrahydroisoquinoline-related compounds, possible MPTP-like neurotoxins, in parkinsonian brain. Niwa T; Takeda N; Yoshizumi H; Tatematsu A; Yoshida M; Dostert P; Naoi M; Nagatsu T Adv Neurol; 1993; 60():234-7. PubMed ID: 8420140 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]